Multidisciplinary Attendee Breakdown
Who Should Attend or Sponsor?
Track 1: Advanced Therapeutics Engineering medicines that change the standard of care
What You’ll Explore
- Engineered cell therapies: CAR-T, TCR, TIL and NK
- Off-the-shelf and in vivo cell therapy platforms
- Breaking the solid-tumor barrier with immune engineering
- Next-generation IO, bispecifics, ADCs and targeted therapy
- Resistance biology, predictive biomarkers and adaptive combinations
- CRISPR, base/prime editing and programmable gene control
- RNA editing, splice modulation, ASOs, siRNA and mRNA
- In vivo delivery, vectors, LNPs and tissue targeting
- Manufacturing, evidence and access from N-of-1 to scale
Who You’ll Meet
- CEOs, Founders, CMOs, CSOs & Heads of R&D — biotech, pharma and advanced-therapy leadership
- Oncology, Hematology & Immunology Chairs — clinicians shaping treatment standards
- Heads of Cell Therapy, Gene Therapy & Genetic Medicines — discovery through translation
- SVPs/VPs of Translational Medicine & Biomarkers — patient selection and response strategy
- Clinical Development & Operations Executives — early-phase through pivotal trials
- Heads of CMC, Manufacturing, Quality & Supply Chain — scale-up and commercialization
- Regulatory, Safety & Pharmacovigilance Leaders — approval and lifecycle risk
- Market Access, Reimbursement & Payer Executives — evidence, coverage and patient access
- Business Development, External Innovation, Corporate Strategy & Venture Leaders — partnerships and capital
Best-Fit Sponsors
- Cell, gene, RNA and genome-editing platforms
- Vector, LNP and targeted-delivery technologies
- CDMOs, CROs and clinical-trial networks
- Cell processing, automation and manufacturing systems
- Potency, release, safety and biomarker assays
- Single-cell, spatial and multi-omics technologies
- ADC, antibody and protein-engineering platforms
- GMP, MES, QMS, eBR and regulatory software
- Cold-chain, logistics and patient-support services
- Clinical-stage biotechs seeking partners and investors
Track 2: AI in Precision Medicine AI that ships, scales and discovers
What You’ll Explore
- Multimodal AI across pathology, imaging, genomics and EHR data
- Computational pathology beyond what the human eye can see
- AI-enabled companion diagnostics and patient selection
- Clinical AI agents and decision support in real workflows
- Foundation models for human biology and medicine
- AI-powered clinical trials and regulatory-grade RWE
- Target discovery, protein design and generative chemistry
- Data infrastructure, MLOps and enterprise deployment
- Safety, governance, evaluation and equitable performance
Who You’ll Meet
- CEOs, Chief AI Officers, Chief Digital Officers & Chief Data Officers — health AI and biopharma leadership
- CIOs, CTOs, CMIOs & Chief Analytics Officers — enterprise clinical deployment
- Heads of AI/ML, Data Science & Computational Biology — pharma, diagnostics and health systems
- Radiology, Pathology & Clinical Informatics Chairs — frontline adoption and validation
- SVPs/VPs of Clinical Development, RWE & Trial Innovation — evidence generation
- Product, Engineering, Platform & MLOps Executives — shipping regulated AI at scale
- Heads of Governance, Safety, Privacy & Cybersecurity — trustworthy deployment
- Digital Health Founders & Clinical Product Leaders — workflow and patient solutions
- Corporate Strategy, Business Development, External Innovation & Investors — partnerships and growth
Best-Fit Sponsors
- Cloud, GPU, accelerator and high-performance-compute providers
- EHR, CDS and interoperability platforms
- Imaging, digital-pathology, PACS and edge-device vendors
- FHIR, ETL, data-lake and enterprise analytics platforms
- Model evaluation, governance, monitoring and audit tools
- RWE, HEOR and clinical-trial analytics companies
- Privacy, security, consent and identity providers
- AI drug-discovery and laboratory-automation platforms
- Annotation, curation and synthetic-data providers
- Digital-health and clinical-AI companies ready to scale
Track 3: Precision Diagnostics Detect earlier, treat smarter, monitor continuously
What You’ll Explore
- Risk-stratified screening and the next generation of early detection
- Methylation, fragmentomics, host response and multimodal signals
- MRD as a treatment-decision engine
- Longitudinal monitoring of resistance, response and relapse
- Companion diagnostics for IO, ADCs and cell therapy
- Integrating tissue, liquid, imaging and clinical biomarkers
- ClinOmics in real clinical practice
- Transplant and organ-health monitoring from blood
- Metagenomic diagnostics for infection and the undiagnosed
- Maternal-fetal diagnostics and actionable non-cancer blood tests
Who You’ll Meet
- CEOs, CMOs, CSOs & Heads of Diagnostics — assay and platform-company leadership
- Oncology, Pathology & Laboratory Medicine Chairs — clinical adoption and standards
- Medical & Scientific Directors of CLIA/CAP Laboratories — validation and operations
- SVPs/VPs of Biomarkers, Companion Diagnostics & Translational Medicine — therapy guidance
- Heads of Early Detection, MRD & Disease Monitoring — oncology and beyond
- Clinical Chiefs in Transplant, Infectious Disease & Maternal-Fetal Medicine — emerging blood-based applications
- Bioinformatics, Computational Genomics & Assay Development Executives — signal to interpretation
- Payer, HTA, Market Access & Health Economics Leaders — utility, coverage and reimbursement
- Regulatory, Quality, Pharma Alliance, Corporate Strategy & Diagnostics Investment Leaders — approval and commercialization
Best-Fit Sponsors
- MCED, MRD and liquid-biopsy platforms
- Multi-disease blood-based diagnostic companies
- Methylation, fragmentomics, cfRNA, EV and proteomic technologies
- Short- and long-read sequencing, sample prep and assay chemistry
- AI diagnostics, interpretation and decision-support software
- Reference laboratories and CLIA testing services
- CDx co-development and clinical-trial assay partners
- Biobanking, pre-analytics, automation and cold-chain providers
- Standards, quality and proficiency-testing organizations
- Market-access, reimbursement and regulatory advisors
Track 4: Genomic Medicine, Implementation & Longevity From sequence to system-wide precision care
What You’ll Explore
- Rare-disease diagnosis beyond the exome
- Newborn sequencing and population genomic screening
- Structural variants, long reads and closing the diagnostic gap
- Moving from genomic diagnosis to targeted treatment
- Precision-medicine operating models that actually work
- EHR integration and decision support clinicians will use
- Coverage, evidence and value-based implementation
- Community access, equity and population-scale delivery
- Aging biology, GLP-1 and prevention
- Biomarkers, wearables and clinical trials for healthspan
Who You’ll Meet
- Health-System CEOs, CMOs, CSOs, CIOs & Chief Strategy Officers — enterprise precision care
- Heads of Genomic Medicine, Rare Disease & Molecular Diagnostics — sequence to action
- Genetics, Pediatrics & Laboratory Medicine Chairs — newborn and rare-disease programs
- SVPs/VPs of Precision Medicine, Population Health & Clinical Transformation — system-wide implementation
- Heads of Bioinformatics, Data Architecture, LIS/LIMS & Interoperability — the operating backbone
- Payer, Value-Based Care, Quality & Evidence Executives — coverage and outcomes
- Heads of Clinical Decision Support, Digital Health & Innovation — workflow adoption
- Geroscience, Metabolic Health & Longevity Institute Leaders — prevention and healthspan
- Business Development, Corporate Strategy, External Innovation & Investors — scaling new models
Best-Fit Sponsors
- WGS, WES, long-read and newborn-screening partners
- Variant interpretation, curation and knowledgebase platforms
- EHR, interoperability and clinical-decision-support vendors
- Cloud data, analytics, governance and integration platforms
- LIS, LIMS, metadata, lineage and workflow systems
- Biobank, registry and sample-management companies
- Payers and value-based-care partners
- Implementation and change-management consultancies
- Aging biomarkers, wearables and digital-endpoint companies
- Prevention, metabolic-health and longevity innovators
Track 5: Precision Frontiers Map tissue, reset immunity, decode the brain
What You’ll Explore
- Spatial transcriptomics, proteomics and tissue architecture
- Human cell atlases and cell-state-driven target discovery
- Spatial pathology, foundation models and clinical biomarkers
- Scaling spatial technologies from discovery to diagnostics
- Immune reset and CAR-T approaches in autoimmune disease
- Tolerance, Tregs and durable disease modification
- Immune signatures, patient stratification and smarter trials
- Blood biomarkers for Alzheimer’s and neurodegeneration
- Precision diagnosis across stroke, epilepsy, Parkinson’s, ALS and FTD
- AI neuroimaging, digital biomarkers and circuit-based therapies
Who You’ll Meet
- CEOs, CMOs, CSOs & Heads of R&D — spatial biology, immunology and neuroscience companies
- Heads of Spatial Biology, Single-Cell Science & Tissue Profiling — atlas to application
- Pathology, Immunology, Rheumatology, Neurology & Neuroscience Chairs — cross-disease clinical leadership
- SVPs/VPs of Translational Medicine, Biomarkers & Precision Research — patient stratification
- Heads of Autoimmune, Neurodegeneration & Brain Health Programs — emerging treatment categories
- Clinical Development, Trial Strategy & Medical Affairs Executives — proof to practice
- Imaging, Digital Biomarker, AI & Computational Biology Leaders — multimodal precision phenotyping
- Business Development, External Innovation & Corporate Strategy Executives — scientific and commercial partnerships
- Venture, Growth & Strategic Investors — building the next precision frontier
Best-Fit Sponsors
- Spatial transcriptomics, proteomics and imaging platforms
- Single-cell, tissue-analysis and digital-pathology technologies
- AI foundation-model and spatial-informatics companies
- Autoimmune and inflammatory-disease biopharma
- Immune-reset, tolerance, Treg and cell-therapy platforms
- Neurodiagnostic, blood-biomarker and reference-lab companies
- Neuroimaging AI, EEG, wearable and digital-biomarker platforms
- Neurology CROs, imaging cores and trial-technology providers
- Biobanks, tissue networks and translational-service partners
- Clinical-stage companies seeking scientific and commercial partners
